Challenges in the use of highly effective modulator treatment for cystic fibrosis.
Challenges in the use of highly effective modulator treatment for cystic fibrosis.
复制标题
DOI:
10.1016/j.jcf.2021.01.007
复制
发表时间:
2021-05
期刊:
影响因子:
--
通讯作者:
Taylor-Cousar JL
中科院分区:
文献类型:
--
作者:
Ramos KJ;Pilewski JM;Taylor-Cousar JL
The last decade has seen development of oral, small molecule therapies that address the basic cystic fibrosis transmembrane conductance regulator (CFTR) protein defect. Highly effective modulator treatment (HEMT) that is efficacious for a large majority of people living with cystic fibrosis (CF) promises to change the landscape of this chronic life-limiting disease. Some people living with CF have a CFTR genotype that renders them eligible for HEMT, but also have comorbidities that excluded them from the original Phase III clinical trials that led to US Food and Drug Administration approval. The purpose of this review is to address the use of HEMT in challenging situations, including initiation for those with advanced CF lung disease, and use after solid organ transplant, during pregnancy, and for individuals with CFTR-related disorders without a definitive diagnosis of CF.
登录
查看更多内容
影响因子:
24.3
作者:
De Muynck, Benedicte;Van Herck, Anke;Vos, Robin
通讯作者:
Vos, Robin
影响因子:
168.9
作者:
Heijerman, Harry G. M.;McKone, Edward F.;Mccoy, Karen S.
通讯作者:
Mccoy, Karen S.
影响因子:
8.9
作者:
Chambers, Daniel C.;Cherikh, Wida S.;Stehlik, Josef
通讯作者:
Stehlik, Josef
DOI:
10.1016/j.jcf.2016.07.011
发表时间:
2017-01
期刊:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
影响因子:
--
作者:
Fink AK;Yanik EL;Marshall BC;Wilschanski M;Lynch CF;Austin AA;Copeland G;Safaeian M;Engels EA
通讯作者:
Engels EA
影响因子:
2.1
作者:
Berastegui, Cristina;Gomez-Olles, Susana;Roman, Antonio
通讯作者:
Roman, Antonio